Business Context and Reporting Period
Company: Synthetic Blood International, Inc. (Note: Request metadata listed "Tenax Therapeutics," but the filing text identifies the registrant as Synthetic Blood International, Inc.)
Reporting Period: Quarterly period ended July 31, 2004.
Status: Development stage company focused on perfluorocarbon-based medical products, specifically "Oxycyte" (a blood substitute), "Fluorovent" (oxygen exchange fluid), and a glucose biosensor implant. The company has no revenue and relies on financing to fund research and development (R&D).
Key Financial Metrics
| Metric | Three Months Ended July 31, 2004 | Three Months Ended July 31, 2003 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(473,422) | $(451,910) |
| Net Loss Per Share | $(0.004) | $(0.005) |
| Cash and Cash Equivalents (End of Period) | $536,621 | $813,676 |
| Working Capital | $237,830 | Not explicitly stated |
| Cash Used in Operating Activities | $(302,565) | $(372,852) |
| Cash Provided by Financing Activities | $612,000 | $1,018,107 |
| Accumulated Deficit (Inception to July 31, 2004) | $(21,423,355) | N/A |
Debt and Liquidity: The company has no long-term debt listed on the balance sheet but has current liabilities of $340,011 (Accounts Payable and Accrued Liabilities). Management estimates cash on hand is sufficient only through October 2004.
Material Changes vs. Prior Period
- Expenses: Total expenses increased slightly by $15,703 to $475,080. Research and Development (R&D) expenses decreased by $13,614 to $219,466, while General and Administrative (G&A) expenses increased by $29,317 to $255,614 due to higher legal/accounting fees and contract management fees.
- Cash Position: Cash and cash equivalents decreased by $277,055 compared to the prior year-end balance, despite a net cash inflow from financing activities of $612,000 during the quarter.
- Financing: The company closed a subscription agreement on May 25, 2004, for $3,030,000. As of July 31, 2004, only $680,000 had been received from three of four investors. The remaining $2,350,000 is contingent on payment from a fourth investor (Remobo AG), which has not been verified.
Outlook, Risks, and Management Commentary
- Going Concern: The filing explicitly states that the company's continuation as a going concern is dependent on obtaining additional financing. There is substantial doubt about the company's ability to continue operations without new capital.
- Product Development: Phase I clinical studies for Oxycyte were completed in December 2003 with results meeting expectations. The company aims to begin Phase II studies in calendar 2004, estimated to cost approximately $2 million and take one year.
- Capital Needs: Management warns that failure to receive the remaining $2.35 million from the foreign investor or secure alternative financing by the end of October 2004 will force the suspension of testing and other activities.
- Risks: Significant risks include the inability to raise capital, the uncertainty of the pending foreign investment, and the long timeline required for FDA approval and commercialization of products.
Investor Verification Checklist
- Capital Runway: Verify if the company has secured funding beyond October 2004, as current cash reserves are insufficient for Phase II trials.
- Pending Investment: Confirm the status of the $2,350,000 subscription from Remobo AG, as management has been unable to verify the delivery of these funds.
- Related Party Transactions: Review the $45,000 in outstanding purchase orders with a specialty manufacturer where an officer of the company is a minority shareholder.
- Regulatory Progress: Monitor the submission of Phase II protocols to the FDA and the timeline for approval.
- Stock Dilution: Assess the potential dilution from the 16.8 million warrants (Series A, B, and C) issued in the recent offering.